Bispecific Antibodies Show Strong Efficacy in Follicular Lymphoma Patients
A recent real-world study indicates that bispecific antibodies achieve high response rates in high-risk individuals with follicular lymphoma. The research also highlighted that these treatments maintain manageable safety profiles, offering a positive outlook for patients facing this type of cancer.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.